Market Overview:
The global angiopoietin 2 market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of cancer, increasing demand for targeted therapies, and growing investments by pharmaceutical companies in R&D for angiopoietin 2 drugs. Based on type, the global angiopoietin 2 market is segmented into Atu-111, BI-836880, LY-3127804, MEDI-3617 and others. Based on application, the market is segmented into hospital care settings (including cancer hospitals), clinic care settings (including oncology clinics) and other end users including research institutes and contract research organizations (CROs). Geographically, the global angiopoietin 2 market is segmented into North America, Latin America Europe Asia Pacific Middle East & Africa.
Product Definition:
Angiopoietin 2 is a protein that helps form new blood vessels. It is important for growth and development, tissue repair, and cancer metastasis.
Atu-111:
Atu-111 is a human growth factor, which is also known as Angiopoietin 2 (APO2). It's structure was first discovered in the 1960s and it was called as angiozyme. The enzyme has since been identified to be an important protein for maintaining vascular integrity. Atu-111 is currently under clinical investigation by Eisai Co., Ltd.
BI-836880:
BI-836880 is a novel, Potent and selective Angiopoietin 2 Inhibitor that targets the pro-apoptotic protein Bcl2 in cells.
Application Insights:
The market is segmented into hospital, clinic and others. The hospital segment dominated the overall application market in 2017 owing to the rising prevalence of cardiovascular diseases and growing government initiatives to reduce healthcare expenditure as a result of which hospitals are considered as the most lucrative end-users of angiopoietin 2 products.
Clinic applications are expected to witness significant growth over the forecast period due to increasing awareness about cardiovascular diseases among patients with diabetes mellitus, high blood pressure levels or those who have had a heart attack. This factor is anticipated to increase product demand in clinics over the forecast period.
Others include independent health facilities, home care settings and other public access sites such as airports and seaports among others where angiopoietin 2 products can be used for treating life-threatening conditions associated with Cardiovascular Diseases (CVDs).
Regional Analysis:
North America dominated the global market in 2017. The U.S., in particular, is one of the most lucrative markets for pharmaceutical companies due to the high prevalence of cardiovascular diseases and other disorders coupled with a well-developed healthcare infrastructure and reimbursement policies that enable access to advanced therapeutics for large patient populations.
Asia Pacific is expected to be one of the fastest growing regions during the forecast period owing to increasing geriatric population, rising disposable income levels, improving lifestyle habits such as smoking cessation and reduction in alcohol consumption among others. Moreover, economic development has led to an increase in construction activities resulting into better facilities for diagnosis & treatment leading thusly increasing demand over time.
Growth Factors:
- Increasing incidence of cardiovascular diseases (CVDs) across the globe is expected to drive the demand for angiopoietin 2 therapies over the forecast period.
- Growing geriatric population is also anticipated to fuel market growth as this population is more susceptible to CVDs.
- Technological advancements in angiopoietin 2 therapies are likely to provide lucrative opportunities for market players over the next few years.
- Rising awareness about available treatment options for CVDs is projected to boost demand for angiopoietin 2 therapies in the near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Angiopoietin 2 Market Research Report
By Type
Atu-111, BI-836880, LY-3127804, MEDI-3617, Others
By Application
Hospital, Clinic, Others
By Companies
Amgen Inc., AnGes MG, Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., MedImmune, LLC, Regeneron Pharmaceuticals, Inc., RXi Pharmaceuticals Corporation, Silence Therapeutics Plc, Synergys Biotherapeutics, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
149
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Angiopoietin 2 Market Report Segments:
The global Angiopoietin 2 market is segmented on the basis of:
Types
Atu-111, BI-836880, LY-3127804, MEDI-3617, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc.
- AnGes MG, Inc.
- Boehringer Ingelheim GmbH
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- MedImmune, LLC
- Regeneron Pharmaceuticals, Inc.
- RXi Pharmaceuticals Corporation
- Silence Therapeutics Plc
- Synergys Biotherapeutics, Inc.
Highlights of The Angiopoietin 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Atu-111
- BI-836880
- LY-3127804
- MEDI-3617
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Angiopoietin 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Angiopoietin 2 is a protein that helps the body create new blood vessels. It also helps to keep existing blood vessels healthy.
Some of the major players in the angiopoietin 2 market are Amgen Inc., AnGes MG, Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., MedImmune, LLC, Regeneron Pharmaceuticals, Inc., RXi Pharmaceuticals Corporation, Silence Therapeutics Plc, Synergys Biotherapeutics, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Angiopoietin 2 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Angiopoietin 2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Angiopoietin 2 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Angiopoietin 2 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Angiopoietin 2 Market Size & Forecast, 2020-2028
4.5.1 Angiopoietin 2 Market Size and Y-o-Y Growth
4.5.2 Angiopoietin 2 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Atu-111
5.2.2 BI-836880
5.2.3 LY-3127804
5.2.4 MEDI-3617
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Angiopoietin 2 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Angiopoietin 2 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Atu-111
9.6.2 BI-836880
9.6.3 LY-3127804
9.6.4 MEDI-3617
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Atu-111
10.6.2 BI-836880
10.6.3 LY-3127804
10.6.4 MEDI-3617
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Atu-111
11.6.2 BI-836880
11.6.3 LY-3127804
11.6.4 MEDI-3617
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Atu-111
12.6.2 BI-836880
12.6.3 LY-3127804
12.6.4 MEDI-3617
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Atu-111
13.6.2 BI-836880
13.6.3 LY-3127804
13.6.4 MEDI-3617
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Angiopoietin 2 Market: Competitive Dashboard
14.2 Global Angiopoietin 2 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen Inc.
14.3.2 AnGes MG, Inc.
14.3.3 Boehringer Ingelheim GmbH
14.3.4 Eli Lilly and Company
14.3.5 F. Hoffmann-La Roche Ltd.
14.3.6 MedImmune, LLC
14.3.7 Regeneron Pharmaceuticals, Inc.
14.3.8 RXi Pharmaceuticals Corporation
14.3.9 Silence Therapeutics Plc
14.3.10 Synergys Biotherapeutics, Inc.
